文章摘要
余昌文,甘亚平,邹 勇,戴丹菁,胡 川.胸腺肽α1联合异甘草酸镁对肝癌经导管肝动脉化疗栓塞术后患者肝纤维化及红细胞免疫功能的影响[J].,2018,(15):2926-2929
胸腺肽α1联合异甘草酸镁对肝癌经导管肝动脉化疗栓塞术后患者肝纤维化及红细胞免疫功能的影响
Effect of Thymosin α1 Combined with Magnesium Isoglycyrrhizinate on Liver Fibrosis and Erythrocyte Immune Function in Patients with Liver Cancer after TACE
投稿时间:2017-11-15  修订日期:2017-12-11
DOI:10.13241/j.cnki.pmb.2018.15.027
中文关键词: 胸腺肽α1  肝癌  红细胞免疫  肝纤维化  经导管肝动脉化疗栓塞
英文关键词: Thymosin α1  Liver cancer  Erythrocyte immune  Liver fibrosis  Transcatheter arterial chemoembolization
基金项目:湖北省卫生计生委西医类重点项目(WJ2015MA028)
作者单位E-mail
余昌文 武汉大学人民医院汉川医院肿瘤科 湖北 汉川 431600 799025261@qq.com 
甘亚平 湖北科技学院病理教研室 湖北 咸宁 437100  
邹 勇 武汉大学人民医院汉川医院肿瘤科 湖北 汉川 431600  
戴丹菁 武汉大学人民医院汉川医院肿瘤科 湖北 汉川 431600  
胡 川 武汉大学人民医院汉川医院肿瘤科 湖北 汉川 431600  
摘要点击次数: 348
全文下载次数: 132
中文摘要:
      摘要 目的:探讨胸腺肽α1联合异甘草酸镁对肝癌经导管肝动脉化疗栓塞(TACE)术后患者肝纤维化及红细胞免疫功能的影响。方法:选择2015年1月至2016年12月间我院应用TACE治疗的肝癌患者84例,根据随机数字表法分为研究组和对照组各42例。两组患者均行TACE治疗,对照组同时给予胸腺肽α1治疗,研究组则应用胸腺肽α1联合异甘草酸镁治疗,疗程均为5 d。比较两组治疗前、治疗5 d后肝功能、肝纤维化指标,并观察患者治疗前、治疗后1个月、3个月、6个月红细胞C3b受体花环率(RBC-C3bRR)、红细胞免疫复合物花环率(RBC-ICR)。结果:治疗5 d后两组患者谷氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)和总胆红素(TBIL)均显著降低,白蛋白(ALB)显著升高(P<0.05),研究组患者ALT、AST、TBIL显著低于对照组,ALB显著高于对照组(P<0.05)。治疗5 d后两组患者血清透明质酸(HA)、III型前胶原氨基末端肽(PCIII)、层粘连蛋白(LN)、IV型胶原(CIV)均显著降低(P<0.05),研究组患者血清HA、LN、PCIII和CIV显著低于对照组(P<0.05)。与治疗前比较,治疗后1个月、3个月、6个月研究组患者的RBC-C3bRR显著升高、RBC-ICR显著降低(P<0.05),且研究组患者RBC-C3bRR显著高于对照组,RBC-ICR显著低于对照组(P<0.05)。结论:胸腺肽α1联合异甘草酸镁可以有效的缓解肝癌TACE术后患者肝纤维化和肝功能损伤,促进红细胞免疫功能的提升,有助于肝癌TACE术后患者的康复。
英文摘要:
      ABSTRACT Objective: To investigate the effect of thymosin α1 combined with Magnesium Isoglycyrrhizinate on liver fibrosis and erythrocyte immune function in patients with liver cancer after transcatheter arterial chemoembolization (TACE) for liver cancer. Methods: 84 patients with liver cancer treated with TACE in our hospital from January 2015 to December 2016 were selected, which were divided into the study group and the control group according to the random number table method, 42 cases in eash group. The patients of two groups were treated with TACE, while the control group was treated with thymosin α1, the study group was treated with thymosin α1 and Magnesium Isoglycyrrhizinate, the course of treatment was 5 days. The liver function and liver fibrosis indexes of two groups were compared before treatment and five days after treatment,and the red blood cell C3b receptor rosette (RBC-C3bRR) and the red blood cell immune complex rosette (RBC-ICR) were observed before treatment, one months, three months, six months after treatment. Results: Five days after treatment, the levels of alanine transaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBIL) in the two groups were significantly decreased, and the level of albumin (ALB) was significantly increased (P<0.05), the ALT, AST and TBIL in the study group were significantly lower than that in the control group, the ALB was significantly higher than that in the control group (P<0.05). Five days after treatment,the levels of serum hyaluronic acid (HA), procollagen type Ⅲ amino-terminal propeptide (PCIII), laminin (LN) and collagen IV (CIV) were significantly decreased in the two groups (P<0.05), the serum HA, LN, PCIII and CIV in the study group were significantly lower than those in the control group (P<0.05). Compared with before treatment, the RBC-C3bRR in the study group was significantly increased and the RBC-ICR decreased significantly one months, three months, six months after treatment (P<0.05), and the RBC-C3bRR in the study group was significantly higher than that in the control group, the RBC-ICR was significantly lower than that in the control group (P<0.05). Conclusion: Thymosin α1 combined with Magnesium Isoglycyrrhizinate can effectively alleviate liver fibrosis and liver function damage in patients with liver cancer after TACE, promote the immune function of red blood cell, it has good therapeutic effect on the rehabilitation of patients with liver cancer after TACE.
查看全文   查看/发表评论  下载PDF阅读器
关闭